Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2023 / Jan / Lowering Lipids – and AMD
Retina Business and Entrepreneurship

Lowering Lipids – and AMD

Researchers find that lipid-lowering and antidiabetic drugs are associated with lower AMD prevalence

By Sarah Healey 1/3/2023 2 min read

Share

Collage images supplied from Rawpixel.com

AMD is the leading cause for severe visual impairment and blindness in high-income countries, particularly in the over-55 age group. In Europe alone, 67 million people are affected by AMD (1) and this figure will only increase as the population continues to age. Despite the condition’s growing prevalence, few preventative interventions are available.

However, new research offers a promising pathway for the future of AMD. In a meta-analysis of 14 population-based and hospital-based European study cohorts, researchers found an association between the systemic use of lipid-lowering drugs (LLDs) and antidiabetic drugs and lower AMD prevalence. As well as lowering serum levels of low-density lipoprotein and triglycerides, some LLDs also have anti-inflammatory and antioxidant properties that affect AMD pathogenesis (1).

Although previous research has investigated the impact of antidiabetic drugs on AMD, these studies conflicted and were not transferable to the general population because they included diabetic patients whose condition could have interfered with AMD pathophysiology. This new study marks the first that meta-analyzes individual-level data, rather than aggregated results.

Despite the study’s promising outcomes, the authors stress its limitations and call for further research. The limitations include issues such as cross-sectional data collection that didn’t assess causality or risk and the fact the patients involved were taking LLDs or antidiabetic drugs for primary purposes, making it impossible to evaluate the drugs’ effects on healthy individuals. Combining these limitations with previous controlled trials that failed to show a causal relationship, it is clear that – although this research paves a new path for the future of AMD treatment – more longitudinal research is needed to better understand the relationship between AMD and systemic medication.

References

  1. MM Mauschitz et al., “Association of lipid-lowering drugs and antidiabetic drugs with age-related macular degeneration: a meta-analysis in Europeans,” Br J Ophthalmol, [Online ahead of print] (2022). PMID: 36344262.

About the Author(s)

Sarah Healey

Communicating stories in a way that is accessible to all was one of the focal points of my Creative Writing degree. Although writing magical realism is a fun endeavor (and one I still dabble in), getting to the heart of human stories has always been the driving motivator behind my writing. At Texere, I am able to connect with the people behind scientific breakthroughs and share their stories in a way that is impactful and engaging.

More Articles by Sarah Healey

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: